SLGL (Sol-Gel Technologies Ltd) רווח נקי

Sol-Gel Technologies revenues are based on licensing royalties from the sale of dermatological products. The company's net profit illustrates the market response to these flows, where the -0.02 mark shows the current state of momentum. Patent disputes and capital requirements limit business stability, however, unique microencapsulation helps effectively counter cheap generics.

Steady confidence from pharmaceutical behemoths in the unique encapsulation method of Sol-Gel Technologies (SLGL) ensures a consistent cash flow that directly impacts the company's profit dynamics. This metric measures the daily balance of net funds after deducting all operating expenses, allowing investors to assess real liquidity reserves and the risk of capital drawdown by analyzing the company's profit trajectory.